Gujarat Kidney and Super Speciality Ltd IPO: Dates, Price Band, Valuation, GMP, Allotment & Review
The mainboard initial public offering (IPO) of 2.20 crore equity shares, without an offer-for-sale component, is being launched by Gujarat Kidney and Super Speciality Limited in order to raise ₹250.80 crore. The initial public offering (IPO) subscription period begins on December 22, 2025, and ends on December 24, 2025. The projected listing date on both the BSE and NSE is December 30, 2025. Each share has a face value of 2 rupees and is priced between 108 and 114 rupees. For retail investors, the minimum investment amount is ₹14,592, and the minimum lot size is 128 shares.
Gujarat Kidney IPO 2025: Dates, Price Band, GMP, Allotment & Review
IPO Issue Structure
| Parameter | Details |
|---|---|
| IPO Type | Fresh Issue |
| Issue Size | ₹250.80 crore (2.20 crore shares) |
| Price Band | ₹108 – ₹114 per share |
| Face Value | ₹2 per share |
| Lot Size | 128 shares |
| Minimum Investment | ₹14,592 (retail) |
| Listing Platform | BSE, NSE |
| IPO Dates | 22–24 Dec 2025 |
| Tentative Listing Date | 30 Dec 2025 |
Application-wise Breakup and Reservation
The IPO is reserved as follows for different investor categories:
-
QIB (Qualified Institutional Buyers): At least 75%
-
NII (Non-Institutional Investors): Up to 15%
-
Retail: Up to 10%
Market Lot Size and Distribution
| Investor Category | Minimum Lots | Minimum Shares | Minimum Amount (₹) |
|---|---|---|---|
| Retail | 1 | 128 | 14,592 |
| S-HNI (Small HNI) | 14 | 1,792 | 2,04,288 |
| B-HNI (Big HNI) | 69 | 8,832 | 10,06,848 |
Gujarat Kidney and Super Speciality Limited Company Overview:
Gujarat Kidney and Super Speciality Limited is more than just a healthcare provider—it’s a beacon of hope for thousands across Gujarat. Born from a vision to make advanced medical care accessible, this multispeciality group has grown rapidly since its inception in 2019, touching lives through its network of seven hospitals and four pharmacies. Each facility is a testament to compassion and innovation, staffed by dedicated doctors, nurses, and support teams who treat every patient with empathy and expertise. From Vadodara to Anand, Gujarat Kidney has become a trusted name, delivering not just treatments but peace of mind to families seeking quality healthcare. With a heart for growth and a mission to heal, the company continues to expand its footprint, ensuring that no one is left behind in their journey to wellness.
Key Performance Indicators (KPIs)
Gujarat Kidney has shown strong financial growth, with revenue increasing from ₹85.79 crore in FY 2023 to ₹119.97 crore in FY 2025. Net profit margin improved from 7.40% to 12.61% during the same period. The company’s ROCE and RONW are also impressive, with ROCE rising from 25.49% to 35.88% and RONW from 30.22% to 38.38%.
Gujarat Kidney IPO Financial Statements:
| KPI | FY 2023 | FY 2024 | FY 2025 (Pre-Issue) | FY 2025 (Post-Issue) |
|---|---|---|---|---|
| Revenue (Cr) | 85.79 | 103.44 | 119.97 | 119.97 |
| Net Income (Cr) | 6.35 | 9.97 | 15.13 | 15.13 |
| Margin (%) | 7.40 | 9.64 | 12.61 | 12.61 |
| EPS (₹) | 1.90 | 2.77 | 2.89 | 1.92 |
| PE Ratio | – | – | 37.37–39.45 | 56.25–59.38 |
| RONW (%) | 30.22 | 43.49 | 38.38 | 38.38 |
| ROCE (%) | 25.49 | 29.37 | 35.88 | 35.88 |
| Debt/Equity | 0.73 | 0.54 | 0.22 | 0.22 |
Valuation Report and Peer Comparison
The pre-IPO market capitalization stands at approximately ₹898.81 crore. Post-IPO, the PE ratio is estimated at 56.25–59.38, which is higher than peers such as Yatharth Hospital (PE: 28.64) and GPT Healthcare (PE: 23.66).
Peer Valuation Table
| Company | PE Ratio | EPS (₹) | RONW (%) | NAV (₹) | Revenue (Cr) |
|---|---|---|---|---|---|
| Gujarat Kidney | 59.38 | 1.92 | 38.38 | 7.53 | 119.97 |
| Yatharth Hospital | 28.64 | 14.46 | 13.09 | 101.84 | 670.55 |
| GPT Healthcare | 23.66 | 5.96 | 21.86 | 26.63 | 400.19 |
IPO Review and GMP
Analysts have highlighted Gujarat Kidney’s rapid revenue and profit growth, but caution that the issue appears greedily priced given the sector’s competitive nature. The Grey Market Premium (GMP) is Rs.10 (9%) as of now.
Anchor and Merchant Bankers
-
Anchor Investors: Not disclosed yet
-
Lead Manager: Nirbhay Capital Services Pvt. Ltd.
-
Registrar: MUFG Intime India Pvt. Ltd.
Allotment Details
Allotment will be finalized on December 26, 2025, with refunds and share crediting by December 29, 2025.
Gujarat Kidney & Super Speciality Ltd IPO Allotment check link: click here
Registrar and Lead Manager Contact
| Name | MUFG Intime India Pvt. Ltd. |
|---|---|
| Address | C-101, 1st Floor, 247 Park L.B.S. Marg, Vikhroli West, Mumbai – 400 083 |
| Phone | +91 810 811 4949 |
| gujaratkidney.ipo@in.mpms.mufg.com | |
| Website | www.in.mpms.mufg.com |
| Name | Nirbhay Capital Services Pvt. Ltd. |
|---|---|
| Address | 201, Maruti Crystal, Opp. Rajpath Club, S.G. Highway, Bodakdev, Ahmedabad 380054 |
| Phone | +91 79 48970649 |
| Website | www.nirbhaycapital.com |
Company Address and Contact
| Name | Gujarat Kidney and Super Speciality Ltd. |
|---|---|
| Address | Plot No. 1, City Sarve No. 1537/A, Jetalpur Road, Gokak Mill Compound, Alkapuri, Vadodara – 390 020, Gujarat |
| Phone | +91 265 298 4800 |
| info@gujaratsuperspecialityhospital.com | |
| Website | www.gujaratsuperspecialityhospital.com |
Mr. Nadim Abbas M G is an Intermediate Chartered Accountant with a strong background in Information Technology. He combines his expertise in IT with a deep understanding of the stock market, making him a valuable resource for both financial and technical insights. With hands-on experience in accounting, IT systems, and stock market analysis, Nadim excels in bridging the gap between finance and technology, offering strategic advice and expert guidance in both domains.
